Download PDF
Diabetologie und Stoffwechsel 2019; 14(05): 362-364
DOI: 10.1055/a-0947-2988
DDG-Preisträger
© Georg Thieme Verlag KG Stuttgart · New York

GIP ist ein Inkretinhormon, das durch westliche Ernährung verstärkt freigesetzt wird und so zu einer ungesunden metabolischen Wirkung beiträgt – Werner-Creutzfeldt-Preis 2019 – eine Kurzübersicht des Preisträgers Andreas F. H. Pfeiffer

Andreas F. H. Pfeiffer
  Abt. Endokrinologie, Diabetes und Ernährungsmedizin, Charité-Universitätsmedizin Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
06 November 2019 (online)

Also available at
    Permissions and Reprints

Ungesunde Ernährung ist eine der Hauptursachen der Zivilisationskrankheiten wie Typ-2-Diabetes (T2DM), Atherosklerose und Demenz. Das Darmhormon glukoseinduziertes insulinotropes Peptid (GIP) wird im oberen Dünndarm durch schnell verdauliche, typischerweise hochverarbeitete, energiedichte Nahrungsmittel freigesetzt und stimuliert die frühe Insulinsekretion und eine effektive Energie-Speicherung und damit die Entstehung der Adipositas, aber auch Insulinresistenz und gestörte Glukosetoleranz. Nahrung, die weniger GIP freisetzt, ist deshalb gesünder.

 

  • Literatur

  • 1 Pfeiffer AFH, Keyhani-Nejad F. High Glycemic Index Metabolic Damage – a Pivotal Role of GIP and GLP-1. Trends Endocrinol Metab 2018; 29: 289-299
    CrossrefPubMedGoogle Scholar
  • 2 Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 2016; 4: 525-536
    CrossrefPubMedGoogle Scholar
  • 3 Miyawaki K, Yamada Y, Ban N. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742
    CrossrefPubMedGoogle Scholar
  • 4 Isken F, Weickert MO, Tschöp MH. et al. Metabolic effects of diets differing in glycaemic index depend on age and endogenous glucose-dependent insulinotrophic polypeptide in mice. Diabetologia 2009; 52: 2159-2168
    CrossrefPubMedGoogle Scholar
  • 5 Rudovich NN, Rochlitz HJ, Pfeiffer AFH. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 2004; 53: 2359-2365
    CrossrefPubMedGoogle Scholar
  • 6 Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000; 66: 91-103
    PubMedGoogle Scholar
  • 7 Yip RG, Boylan MO, Kieffer TJ. et al. Functional GIP receptors are present on adipocytes. Endocrinology 1998; 139: 4004-4007
    CrossrefPubMedGoogle Scholar
  • 8 Gogebakan O, Osterhoff MA, Schueler R. et al. GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. Diabetologia 2015; 58: 1759-1768
    CrossrefPubMedGoogle Scholar
  • 9 Pivovarova O, Hornemann S, Weimer S. et al. Regulation of nutrition-associated receptors in blood monocytes of normal weight and obese humans. Peptides 2015; 65C: 12-19
    Google Scholar
  • 10 Wernstedt Asterholm I, Tao C, Morley TS. et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab 2014; 20: 103-118
    CrossrefPubMedGoogle Scholar
  • 11 Kruse M, von Loeffelholz C, Hoffmann D. et al. Dietary rapeseed/canola-oil supplementation reduces serum lipids and liver enzymes and alters postprandial inflammatory responses in adipose tissue compared to olive-oil supplementation in obese men. Mol Nutr Food Res 2015; 59: 507-519
    CrossrefPubMedGoogle Scholar
  • 12 Spranger J, Kroke A, Möhlig M. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817
    CrossrefPubMedGoogle Scholar
  • 13 Gogebakan O, Andres J, Biedasek K. et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11beta-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012; 61: 292-300
    CrossrefPubMedGoogle Scholar
  • 14 Masuzaki H, Paterson J, Shinyama H. et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170
    CrossrefPubMedGoogle Scholar
  • 15 Rudovich N, Kaiser S, Engeli S. et al. GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women. Regul Pept 2007; 142: 138-145
    CrossrefPubMedGoogle Scholar
  • 16 Honka H, Koffert J, Kauhanen S. et al. Liver blood dynamics after bariatric surgery: the effects of mixed-meal test and incretin infusions. Endocr Connect 2018; 7: 888-896
    CrossrefPubMedGoogle Scholar
  • 17 Honka H, Koffert J, Kauhanen S. et al. Bariatric Surgery Enhances Splanchnic Vascular Responses in Patients With Type 2 Diabetes. Diabetes 2017; 66: 880-885
    CrossrefPubMedGoogle Scholar
  • 18 Asmar M, Asmar A, Simonsen L. et al. The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes 2017; 66: 2363-2371
    CrossrefPubMedGoogle Scholar
  • 19 Keyhani-Nejad F, Kemper M, Schueler R. et al. Effects of Palatinose and Sucrose Intake on Glucose Metabolism and Incretin Secretion in Subjects With Type 2 Diabetes. Diabetes Care 2016; 39: e38-e39
    CrossrefPubMedGoogle Scholar
  • 20 Keyhani-Nejad F, Irmler M, Isken F. et al. Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice. Diabetologia 2015; 58: 374-383
    CrossrefPubMedGoogle Scholar